Graham Capital Management, L.P. Ascendis Pharma A/S Transaction History
Graham Capital Management, L.P.
- $4.42 Billion
- Q3 2024
A detailed history of Graham Capital Management, L.P. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Graham Capital Management, L.P. holds 1,872 shares of ASND stock, worth $258,336. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,872
Previous 2,502
25.18%
Holding current value
$258,336
Previous $341,000
18.18%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ASND
# of Institutions
244Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.34 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$708 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$688 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$609 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$578 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.7B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...